Research programme: apoptosis inducers - Celera Genomics/EpiCept
Alternative Names: Apoptosis inducers research programme - Celera Genomics/Maxim; MX 11697Latest Information Update: 17 Mar 2008
At a glance
- Originator Celera Genomics Group; EpiCept Corporation
- Developer Celera Group; EpiCept Corporation
- Class Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Mar 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 09 Jan 2006 Maxim Pharmaceuticals has been acquired and merged into EpiCept Corporation
- 20 Jun 2005 This programme is still in active development